

**ASX ANNOUNCEMENT
Lifespot Health Limited**

ASX: LSH 20th June 2018

**Discussions underway with Cannabis producers to finance
vertically integrated models of both medicinal and
recreational cannabis products**

- **In discussions with North American and Australasian Cannabis producers to finance vertically integrated production models**
- **The recent proposal of Bill C-45 to legalise recreational marijuana use in Canada, along with other pending legislation changes in Australasia regions presents huge first mover advantage**
- **Seng Vital Vaporizer on Body Tel platform delivering CBD specific dosages and managing patient safety and compliance, prototype due in 5 weeks**
- **Featured at the international cannabis expo in June 2018**
- **LSH has also had discussions with several corporate advisors, broking firms and strategic partners in Canada, to spin-off the Seng-Vital vaporizer and its technology platform, as a potential IPO on the Canadian Stock Exchange (CSE)**

CANNABIS OPPORTUNITIES

Lifespot Health Ltd. is pleased to advise that it has entered into discussions with North American and Australasian cannabis companies to finance the vertically integrated production of both medicinal and recreational cannabis products.

The Company is currently assessing strategic opportunities in the cannabis sector, that go beyond the production of cannabis and selling of the bud, by taking a step further in processing it to become end products CBD, THC etc, which have much higher margins.

Legal marijuana sales in the U.S. are estimated to grow by more than 27% per year through 2022 (assuming peak sales estimates each year). After hitting a peak of \$6.6 billion in legal sales in 2017, Factbook estimates that between \$18 billion and \$22.1 billion worth of cannabis could be sold to consumers through legal channels in 2022.¹

LSH considers that the recent proposal of Bill C-45 to legalise recreational marijuana use in Canada, along with other pending legislation changes in Australasia regions presents huge first mover advantage, and as such, is in advanced discussions with numerous parties.

LSH also confirms it is currently in discussions with broking houses to act as corporate adviser to any such transaction. An update will be made in due course.

SENG VITAL LAUNCH

The Seng -Vital vaporizer allows cannabis to be taken in the form of vapours extracted from oils or herbs. What makes the vaporizer unique is its embedment in the medically certified software infrastructure of BodyTel GmbH, a wholly owned subsidiary of Lifespot Health Ltd. The BodyTel infrastructure allows consumers, patients and authorized physicians to retrieve and evaluate the readings and data collected by the vaporizer, controlling the application history via the BodyTel Data Monitoring & Collection.

In addition, the vaporizer is equipped with unique security features developed by Seng Vital. Central elements of the concept are the integration of a fingerprint sensor and the authorization of the active ingredient capsules based on the processing of the central pharmaceutical number (PZN, nationwide central key for pharmaceuticals). Through these elements, the vaporizer has the potential to be recognized as a medical device by the US Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA), and also be a viable recreational delivery system with appropriate security and safety systems to ensure proper recreation use.

Lifespot subsidiary Seng Vital Pty. Ltd., in which Lifespot Health holds a 50 percent interest, confirm that the reference standard and operating prototype of the Seng-Vital and Bodytel integrated platform will be completed in 5 weeks, ready for trials and calibration with cannabis products.

The integrated vaporiser will deliver a calibrated dose of cannabis to patients and provide valuable dosage and tracking data to ensure safety and compliance of this new therapy.

Heiner Emden, Executive Director of Lifespot Health Ltd. & Managing Director of BodyTel GmbH said “our integrated platform is the perfect delivery system for registered prescribers and large Pharmaceutical companies that are developing new cannabis products. Safety, compliance and efficacy are the key elements for any new medication and we are delighted to be able to provide this system to enable best practice cannabis delivery. In addition, we believe our platform is the perfect partner for countries approving recreational cannabis where safety and responsible usage are most important”.

Lifespot will attend the International Cannabis Convention in Canada June 24-25 to showcase the integrated system and seek to partnerships with North American companies and Multinational Pharmaceutical companies.

1. Marijuana Business Daily - Marijuana Business Factbook

For further information:

Mr Justyn Stedwell
Company Secretary
(03) 9191 0135

About Lifespot Health Ltd.

Lifespot Health an ISO 13485 certified company, operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology. Our systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money. Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients and healthcare professionals to efficiently monitor chronic diseases and critical conditions on their personal and professional digital devices including Smartphone, iPad / Tablets and desktop.

For personal use only